These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11138460)

  • 21. Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 Non-Small Cell Lung Cancer Cells.
    Xu B; Tao ZZ
    Oncol Res; 2014; 22(4):213-217. PubMed ID: 26351210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic interaction of hyperthermia and Gemcitabine in lung cancer.
    Vertrees RA; Das GC; Popov VL; Coscio AM; Goodwin TJ; Logrono R; Zwischenberger JB; Boor PJ
    Cancer Biol Ther; 2005 Oct; 4(10):1144-53. PubMed ID: 16138007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
    Zhang HH; Zhang ZY; Che CL; Mei YF; Shi YZ
    Int J Clin Exp Pathol; 2013; 6(9):1734-46. PubMed ID: 24040438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
    Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
    Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
    Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
    Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
    Wang X; Chen F; Gou S
    Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.
    Li L; Schaid DJ; Fridley BL; Kalari KR; Jenkins GD; Abo RP; Batzler A; Moon I; Pelleymounter L; Eckloff BW; Wieben ED; Sun Z; Yang P; Wang L
    Pharmacogenet Genomics; 2012 Feb; 22(2):105-16. PubMed ID: 22173087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.
    Zhang Y; Schwerbrock NM; Rogers AB; Kim WY; Huang L
    Mol Ther; 2013 Aug; 21(8):1559-69. PubMed ID: 23774791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer.
    Gazzaniga P; Silvestri I; Gradilone A; Scarpa S; Morrone S; Gandini O; Gianni W; Frati L; Aglianò AM
    Anticancer Drugs; 2007 Feb; 18(2):179-85. PubMed ID: 17159604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine.
    Zhao C; Yue B; Liu H; Sun C; Li W; Qu X
    Toxicol Appl Pharmacol; 2012 Aug; 262(3):293-300. PubMed ID: 22617428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-X-C chemokine receptor 2 correlates with unfavorable prognosis and facilitates malignant cell activities via activating JAK2/STAT3 pathway in non-small cell lung cancer.
    Wei L; Liu Y; Ma Y; Ding C; Zhang H; Lu Z; Gu Z; Zhu C
    Cell Cycle; 2019 Dec; 18(24):3456-3471. PubMed ID: 31731888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
    Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
    Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
    Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
    Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.
    Gridelli C; Cigolari S; Gallo C; Manzione L; Ianniello GP; Frontini L; Ferraù F; Robbiati SF; Adamo V; Gasparini G; Novello S; Perrone F;
    Lung Cancer; 2001; 31(2-3):277-84. PubMed ID: 11165408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging role of gemcitabine in lung cancer: part I.
    Bunn PA
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-1. PubMed ID: 9194472
    [No Abstract]   [Full Text] [Related]  

  • 40. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
    Zoli W; Ricotti L; Dal Susino M; Barzanti F; Frassineti GL; Folli S; Tesei A; Bacci F; Amadori D
    Br J Cancer; 1999 Oct; 81(4):609-15. PubMed ID: 10574245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.